Our top pick for
Building a portfolio
Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.
AIkido Pharma Inc is a biotechnology business based in the US. AIkido Pharma shares (AIKI) are listed on the NASDAQ and all prices are listed in US Dollars. AIkido Pharma employs 4 staff and has a trailing 12-month revenue of around USD0.00.
|52-week range||USD$0.47 - USD$2.55|
|50-day moving average||USD$1.20|
|200-day moving average||USD$0.95|
|Wall St. target price||USD$19.00|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||USD$-1.97|
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Valuing AIkido Pharma stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of AIkido Pharma's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
AIkido Pharma's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 3x. In other words, AIkido Pharma shares trade at around 3x recent earnings.
That's relatively low compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The low P/E ratio could mean that investors are pessimistic about the outlook for the shares or simply that they're under-valued.
|Gross profit TTM||USD$9,000|
|Return on assets TTM||-19.59%|
|Return on equity TTM||-61.46%|
|Market capitalisation||USD$82.9 million|
TTM: trailing 12 months
There are currently 2.0 million AIkido Pharma shares held short by investors – that's known as AIkido Pharma's "short interest". This figure is 267.8% up from 542,068 last month.
There are a few different ways that this level of interest in shorting AIkido Pharma shares can be evaluated.
AIkido Pharma's "short interest ratio" (SIR) is the quantity of AIkido Pharma shares currently shorted divided by the average quantity of AIkido Pharma shares traded daily (recently around 99.7 million). AIkido Pharma's SIR currently stands at 0.02. In other words for every 100,000 AIkido Pharma shares traded daily on the market, roughly 20 shares are currently held short.
However AIkido Pharma's short interest can also be evaluated against the total number of AIkido Pharma shares, or, against the total number of tradable AIkido Pharma shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case AIkido Pharma's short interest could be expressed as 0.01% of the outstanding shares (for every 100,000 AIkido Pharma shares in existence, roughly 10 shares are currently held short) or 0.0061% of the tradable shares (for every 100,000 tradable AIkido Pharma shares, roughly 6 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against AIkido Pharma.
Find out more about how you can short AIkido Pharma stock.
We're not expecting AIkido Pharma to pay a dividend over the next 12 months.
AIkido Pharma's shares were split on a 1113:1000 basis on 27 October 2019. So if you had owned 1000 shares the day before before the split, the next day you'd have owned 1113 shares. This wouldn't directly have changed the overall worth of your AIkido Pharma shares – just the quantity. However, indirectly, the new 10.2% lower share price could have impacted the market appetite for AIkido Pharma shares which in turn could have impacted AIkido Pharma's share price.
Over the last 12 months, AIkido Pharma's shares have ranged in value from as little as $0.4656 up to $2.55. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while AIkido Pharma's is 1.6238. This would suggest that AIkido Pharma's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
AIkido Pharma Inc. , a biotechnology company, focuses on developing small-molecule anti-cancer therapeutics. Its pipeline of therapeutics includes therapies for pancreatic cancer, acute myeloid leukemia, and acute lymphoblastic leukemia. It is developing DHA-dFdC, a pancreatic drug candidate; and KPC34, a small molecule treatment for acute myeloid leukemia and acute lymphoblastic leukemia. The Company is also developing an antiviral platform that inhibits replication of multiple viruses, including influenza virus, SARS-CoV, MERS-CoV, Ebolavirus, and Marburg virus. It has a license agreement with the University of Texas; and Wake Forest University Health Sciences. The company was formerly known as Spherix Incorporated and changed its name to AIkido Pharma Inc.
Steps to owning and managing TREB-U, with 24-hour and historical pricing before you buy.
Steps to owning and managing TIG, with 24-hour and historical pricing before you buy.
Steps to owning and managing TDAC, with 24-hour and historical pricing before you buy.
Steps to owning and managing TREB, with 24-hour and historical pricing before you buy.
Steps to owning and managing TREB-WS, with 24-hour and historical pricing before you buy.
Steps to owning and managing TDG, with 24-hour and historical pricing before you buy.
Steps to owning and managing TACT, with 24-hour and historical pricing before you buy.
Steps to owning and managing TT, with 24-hour and historical pricing before you buy.
Steps to owning and managing TROX, with 24-hour and historical pricing before you buy.
Steps to owning and managing TRVG, with 24-hour and historical pricing before you buy.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.